WallStSmart

Champions Oncology Inc (CSBR)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 111922% more annual revenue ($66.57B vs $59.42M). MRK leads profitability with a 4.8% profit margin vs -2.0%. MRK earns a higher WallStSmart Score of 36/100 (F).

CSBR

Avoid

25

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 3.5
Piotroski: 4/9Altman Z: -2.04

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CSBRUndervalued (+42.5%)

Margin of Safety

+42.5%

Fair Value

$10.26

Current Price

$5.10

$5.16 discount

UndervaluedFair: $10.26Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CSBR0 strengths · Avg: 0/10

No standout strengths identified

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

CSBR4 concerns · Avg: 3.0/10
Price/BookValuation
18.2x4/10

Trading at 18.2x book value

Market CapQuality
$70.98M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.173/10

Elevated debt levels

Return on EquityProfitability
-53.3%2/10

ROE of -53.3% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CSBR

Revenue growth of 12.0% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : CSBR

The primary concerns for CSBR are Price/Book, Market Cap, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

CSBR profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

CSBR carries more volatility with a beta of 0.40 — expect wider price swings.

CSBR is growing revenue faster at 12.0% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 25/100). CSBR offers better value entry with a 42.5% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Champions Oncology Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. The company is headquartered in Hackensack, New Jersey.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?